ConductScience.org, home

Paper40868931

A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases.

Leong EYX and 8 others. Life (Basel), 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases. Papers, record 40868931. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40868931

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases.
PubMed
Journal
Life (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
2.11, provisional
iCite
Revised in PubMed
2025-09-14
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leong EYXElizabeth Y Xhttps://orcid.org/0000-0001-5493-3445
2Ding JJianbin
3Wu DDuoduohttps://orcid.org/0000-0002-2247-0949
4Lim BXHBlanche X Hhttps://orcid.org/0000-0001-6930-5046
5Ang AAndrea
6Wong EEvanhttps://orcid.org/0000-0002-5466-1176
7Morlet NNigel
8Mehta JSJodhbir Shttps://orcid.org/0000-0001-6362-4898
9Lim CHLChris H Lhttps://orcid.org/0000-0003-2219-3184

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References150

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119907920Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.Cell Mol Life Sci2010https://conductscience.org/library/papers/19907920PubMed
235993293Rho-kinase inhibitors: Role in corneal endothelial disorders.Semin Ophthalmol2023https://conductscience.org/library/papers/35993293PubMed
318085464Immune mechanisms of corneal allograft rejection.Curr Eye Res2007https://conductscience.org/library/papers/18085464PubMed
438479724Rho-kinase inhibitor alleviates CD4+T cell mediated corneal graft rejection by modulating its STAT3 and STAT5 activation.Exp Eye Res2024https://conductscience.org/library/papers/38479724PubMed
520478312Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells.J Mol Cell Cardiol2010https://conductscience.org/library/papers/20478312PubMed
640120926Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells.Exp Eye Res2025https://conductscience.org/library/papers/40120926PubMed
715548136PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.Biochem J2005https://conductscience.org/library/papers/15548136PubMed
838689101The Protective Effect of Rho-Associated Kinase Inhibitor Eye Drops (Ripasudil) on Corneal Endothelial Cells After Cataract Surgery: A Prospective Comparative Study.Ophthalmol Ther2024https://conductscience.org/library/papers/38689101PubMed
922898649Corneal neovascularization: an anti-VEGF therapy review.Surv Ophthalmol2012https://conductscience.org/library/papers/22898649PubMed
1025823914The effects of Rho-associated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media approach.Sci Rep2015https://conductscience.org/library/papers/25823914PubMed
1132672669Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.Ophthalmol Glaucoma2019https://conductscience.org/library/papers/32672669PubMed
1230098200The Corneal Basement Membranes and Stromal Fibrosis.Invest Ophthalmol Vis Sci2018https://conductscience.org/library/papers/30098200PubMed
1336637659Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment.Ophthalmol Ther2023https://conductscience.org/library/papers/36637659PubMed
1423462749The ROCK inhibitor eye drop accelerates corneal endothelium wound healing.Invest Ophthalmol Vis Sci2013https://conductscience.org/library/papers/23462749PubMed
1533859757Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension.Theranostics2021https://conductscience.org/library/papers/33859757PubMed
1625811020Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery.Biomed Res Int2015https://conductscience.org/library/papers/25811020PubMed
1735150417Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.Adv Ther2022https://conductscience.org/library/papers/35150417PubMed
1835037906Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature.Cornea2022https://conductscience.org/library/papers/35037906PubMed
1930386798Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.Med Hypothesis Discov Innov Ophthalmol2018https://conductscience.org/library/papers/30386798PubMed
2039730553Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.Sci Rep2024https://conductscience.org/library/papers/39730553PubMed

See all 150 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42593179Targeting RhoA/ROCK Signaling to Modulate Extracellular Matrix Remodeling in Corneal Endothelial Dystrophies.Invest Ophthalmol Vis Sci2026https://conductscience.org/library/papers/42593179PubMed
41669778Emerging in vitro models of corneal stromal fibrosis: Toward human-relevant platforms for anti-scarring therapeutics.Indian J Ophthalmol2026https://conductscience.org/library/papers/41669778PubMed
41313356Exploring corneal endothelial cell dynamics: structure, functions and therapeutic approaches.Mol Biol Rep2025https://conductscience.org/library/papers/41313356PubMed
40943853RhoKinase (ROCK) Inhibition as a Therapeutic Strategy for Pseudophakic Bullous Keratopathy: A Comprehensive Review.J Clin Med2025https://conductscience.org/library/papers/40943853PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ROCK16093PubTator's text mininghttps://conductscience.org/library/genes/6093

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40868931

GET https://conductscience.org/api/papers/v1/40868931/references?page=2